EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona Case

Pilar Puig-Serra, Ana Hinckley-Boned, María Tristán-Manzano iD, Paula Rio, Raul Torres-Ruiz, Sandra Rodriguez-Perales, Francisco Martín iD

Human Gene Therapy · 2025

DOI: 10.1177/10430342251372474 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Pilar Puig-Serra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. Hauptthemen laut MEDLINE: Lentivirus, Genetic Vectors, Genetic Therapy, Hematopoietic Stem Cells. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 86 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Seven cases of hematological malignancy reported in recipients of Skysona™ (elivaldogene autotemcel) have reignited long-standing concerns about insertional mutagenesis in lentiviral vector (LV)-based gene therapy. Here, we dissect the molecular and clinical evidence underlying these events, place them in the broader context of over 300 patients treated with LV-modified hematopoietic stem and progenitor cells (HSPCs), and review the real-world safety record of LV-engineered chimeric antigen receptor T cells. We show that cancers associated with Skysona are mechanistically linked to the use of a potent viral MNDU3 promoter probably combined with intensive conditioning and growth-factor support, whereas LV products employing weak or physiological promoters continue to display an excellent safety profile. With event rates

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LentivirusGenetic VectorsGenetic TherapyHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHematologic NeoplasmsHumansRisk AssessmentMutagenesis, Insertional

Stichwörter der Autor:innen

Skysonagene therapy safetygenotoxicityhematopoietic stem cellsinsertional mutagenesislentiviral vectors

Autor:innen und Institutionen

  • Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • GENYO, Centre for Genomics and Oncological Research: Pfizer, Andalusian Regional Government PTS Granada, University of Granada, Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
  • LentiStem Biotech, Granada, Spain.
  • Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas, Madrid, Spain.
  • Advanced Therapies Unit, Instituto de Investigacion Sanitaria Fundacion Jimenez Díaz, Universidad Autonoma de Madrid, Madrid, Spain.

ORCID-Profile: María Tristán-Manzano, Francisco Martín

Zitieren

APA

Puig-Serra, P., Hinckley-Boned, A., Tristán-Manzano, M., Rio, P., Torres-Ruiz, R., Rodriguez-Perales, S., & Martín, F. (2025). Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona Case. Human Gene Therapy. https://doi.org/10.1177/10430342251372474

Vancouver

Puig-Serra P, Hinckley-Boned A, Tristán-Manzano M, Rio P, Torres-Ruiz R, Rodriguez-Perales S, et al. Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona Case. Human Gene Therapy. 2025. doi:10.1177/10430342251372474

BibTeX
@article{PuigSerra2025,
  author = {Puig-Serra, Pilar and Hinckley-Boned, Ana and Tristán-Manzano, María and Rio, Paula and Torres-Ruiz, Raul and Rodriguez-Perales, Sandra and Martín, Francisco},
  title = {Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona Case},
  journal = {Human Gene Therapy},
  year = {2025},
  doi = {10.1177/10430342251372474}
}
Kostenlos starten →